Concepedia

Oral administration of a low dose of midazolam (75�?g) as an in vivo probe for CYP3A activity

Chin B. Eap, Thierry Buclin, Gianni Cucchia, Daniele Zullino, Elisabeth Hustert, Gabriela Bleiber, KerryPowell Golay, Anne-Catherine Aubert, Pierre Baumann, Amalio Telenti,

European Journal of Clinical Pharmacology · 2004 · 95 citations · 20 references

DOIFull text

Open access

Concepts

References

20

Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein

Richard B. Kirn, Christoph Wandel, Brenda F. Leake et al. · Pharmaceutical Research · 1999 · 460 citations

, , +10

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin*

Jack Gorski, D. I. Jones, B HAEHNERDANIELS et al. · Clinical Pharmacology & Therapeutics · 1998 · 411 citations

, , +14

Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients.

Kenneth E. Thummel, Danny D. Shen, Terry Podoll et al. · Journal of Pharmacology and Experimental Therapeutics · 1994 · 356 citations

, , +17

Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole

Anu Varhe, Klaus T. Olkkola, Pertti J. Neuvonen · Clinical Pharmacology & Therapeutics · 1994 · 280 citations

, , +15

Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole

Shirley M. Tsunoda, R VELEZ, L VONMOLTKE et al. · Clinical Pharmacology & Therapeutics · 1999 · 258 citations

, , +17